Tags

Type your tag names separated by a space and hit enter

What's Old and New in Tuberculosis Vaccines for Children.
J Pediatric Infect Dis Soc. 2022 Oct 31; 11(Supplement_3):S110-S116.JP

Abstract

Tuberculosis (TB) is a leading cause of global child mortality. Until the turn of the 21st century, Mycobacterium bovis bacille Calmette-Guerin (BCG) was the only vaccine to prevent TB. The pediatric TB vaccine pipeline has advanced in the past decade to include the evaluation of novel whole cell vaccines to replace infant BCG and investigation of subunit and whole cell vaccines to boost TB immunity during adolescence. We describe the history of BCG, current TB vaccine candidates in clinical trials, and the challenges and opportunities for future TB vaccine research in children. Children are a critical target population for TB vaccines, and expansion of the pediatric TB vaccine pipeline is urgently needed to end the TB pandemic.

Links

PMC Free PDF

Authors+Show Affiliations

Cranmer LM
Department of Pediatrics, Division of Pediatric Infectious Disease, Emory School of Medicine, Atlanta, Georgia, USA. Department of Epidemiology, Emory Rollins School of Public Health, Atlanta, Georgia, USA. Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Cotton MF
Department of Pediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa.
Day CL
Department of Microbiology & Immunology, Emory School of Medicine, Atlanta, Georgia, USA. Emory Vaccine Center, Atlanta, Georgia, USA.
Nemes E
South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.

MeSH

HumansChildTuberculosis VaccinesBCG VaccineMycobacterium bovisTuberculosisMycobacterium tuberculosis

Pub Type(s)

Journal Article

Language

eng

PubMed ID

36314550

Citation

Cranmer, Lisa M., et al. "What's Old and New in Tuberculosis Vaccines for Children." Journal of the Pediatric Infectious Diseases Society, vol. 11, no. Supplement_3, 2022, pp. S110-S116.
Cranmer LM, Cotton MF, Day CL, et al. What's Old and New in Tuberculosis Vaccines for Children. J Pediatric Infect Dis Soc. 2022;11(Supplement_3):S110-S116.
Cranmer, L. M., Cotton, M. F., Day, C. L., & Nemes, E. (2022). What's Old and New in Tuberculosis Vaccines for Children. Journal of the Pediatric Infectious Diseases Society, 11(Supplement_3), S110-S116. https://doi.org/10.1093/jpids/piac078
Cranmer LM, et al. What's Old and New in Tuberculosis Vaccines for Children. J Pediatric Infect Dis Soc. 2022 Oct 31;11(Supplement_3):S110-S116. PubMed PMID: 36314550.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - What's Old and New in Tuberculosis Vaccines for Children. AU - Cranmer,Lisa M, AU - Cotton,Mark F, AU - Day,Cheryl L, AU - Nemes,Elisa, PY - 2023/10/31/pmc-release PY - 2022/10/31/entrez PY - 2022/11/1/pubmed PY - 2022/11/2/medline KW - child KW - tuberculosis KW - vaccine SP - S110 EP - S116 JF - Journal of the Pediatric Infectious Diseases Society JO - J Pediatric Infect Dis Soc VL - 11 IS - Supplement_3 N2 - Tuberculosis (TB) is a leading cause of global child mortality. Until the turn of the 21st century, Mycobacterium bovis bacille Calmette-Guerin (BCG) was the only vaccine to prevent TB. The pediatric TB vaccine pipeline has advanced in the past decade to include the evaluation of novel whole cell vaccines to replace infant BCG and investigation of subunit and whole cell vaccines to boost TB immunity during adolescence. We describe the history of BCG, current TB vaccine candidates in clinical trials, and the challenges and opportunities for future TB vaccine research in children. Children are a critical target population for TB vaccines, and expansion of the pediatric TB vaccine pipeline is urgently needed to end the TB pandemic. SN - 2048-7207 UR - https://www.unboundmedicine.com/medline/citation/36314550/What's_Old_and_New_in_Tuberculosis_Vaccines_for_Children_ DB - PRIME DP - Unbound Medicine ER -